Core Viewpoint - The company announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has proposed to be selected for the national centralized procurement of clarithromycin tablets and simvastatin tablets, with the procurement period extending until December 31, 2028 [1] Group 1 - The total sales revenue for the two products in 2024 is projected to be 38.99 million yuan, which accounts for 11.81% of the company's total revenue [1] - If the purchase and sales agreement is signed, it will expand the sales scale of the company [1]

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd., has participated in the national centralized procurement for drugs whose agreements are expiring, with some products expected to be selected for procurement [1] Group 1: Procurement Participation - Zhejiang Beid Pharmaceutical has submitted applications for the national centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement selection were published by the procurement office on February 10, 2026, indicating that some products from Beid Pharmaceutical are likely to be selected [1] Group 2: Selected Products and Financial Impact - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets, both of which are included in the national medical insurance catalog [1] - For the year 2024, the sales revenue of Clarithromycin tablets is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue of Simvastatin tablets is projected to be 1.71 million yuan, representing 0.52% of the company's main business income during the same period [1]

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd. (referred to as "Beid Pharmaceutical"), has participated in the national centralized procurement for drugs whose agreements are expiring, and some of its products are expected to be selected in this procurement process [1] Group 1 - Beid Pharmaceutical has submitted applications for the national organized centralized procurement for drugs whose agreements are expiring, excluding insulin [1] - The results of the procurement process, published by the procurement office on February 10, 2026, indicate that some of Beid Pharmaceutical's products are likely to be selected [1] - The products expected to be selected include Clarithromycin Tablets and Simvastatin Tablets, both of which are included in the national medical insurance catalog [1]

Core Viewpoint - The company Sunflower (300111.SZ) announced that its subsidiary, Zhejiang Beid Pharmaceutical Co., Ltd. (referred to as "Beid Pharmaceutical"), has participated in the national centralized procurement for drugs whose agreements are expiring, and some of its products are proposed to be selected in this procurement process [1] Group 1 - Beid Pharmaceutical has submitted applications for the national centralized procurement of drugs as part of the first to eighth batches, excluding insulin [1] - The proposed selected products from Beid Pharmaceutical include Clarithromycin Tablets and Simvastatin Tablets, both of which are listed in the national medical insurance catalog [1]

Core Viewpoint - The company Sunflower announced that its subsidiary, Beid Pharmaceutical, is participating in the continuation procurement of drugs from the national organized procurement batches 1-8, with some products expected to be selected [1] Group 1: Selected Products - The products expected to be selected include Clarithromycin tablets and Simvastatin tablets [1] - The procurement period for the selected products will last from the actual execution date of the selection results until December 31, 2028 [1] Group 2: Financial Impact - The sales revenue for Clarithromycin tablets in 2024 is projected to be 37.18 million yuan, accounting for 11.29% of the company's main business income during the same period [1] - The sales revenue for Simvastatin tablets is expected to be 1.71 million yuan, representing 0.52% of the company's main business income for the same period [1]